Research  >  About SRI  >  Scientist Profiles
Share:  
|
PAGE
MENU

Scientist profiles M-R

SRI Profiles

Mario Masellis, M.Sc. (Pharm), MD, PhD, FRCPC

Associate scientist

Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room A4 55
Toronto, ON
M4N 3M5

Phone: 416-480-6100, ext. 89351
Fax: 416-480-5354

For research inquiries: Stephanie Hetherington and Kathryn Sharp
Phone: 416-480-6100, ext. 1620
Email: stephanie.hetherington@sunnybrook.ca, kathryn.sharp@sunnybrook.ca

For clinical inquiries: Karina Subhanie
Phone: 416-480-6100, ext. 89351
Email: karina.subhanie@sunnybrook.ca

Education:

  • B.Sc., 1994, pharmacology, University of Toronto, Canada
  • M.Sc., 1997, pharmacology, U of T, Canada
  • MD, 2001, medicine, U of T, Canada
  • PhD, 2012, clinical neurosciences, U of T, Canada

Appointments and Affiliations:

  • Associate scientist, Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute
  • Assistant professor, neurology, department of medicine, U of T
  • Research scientist, neurogenetics, Centre for Addiction and Mental Health
  • Clinician-scientist, neurology, department of medicine, Sunnybrook Health Sciences Centre
  • Consultant neurologist, neurology, department of medicine, Sunnybrook
  • Co-director, cognitive neurology research unit, department of medicine, Sunnybrook
  • Director, movement disorders clinic, department of medicine, Sunnybrook

    Research Focus:

    • Genetics of neurodegenerative and neuropsychiatric disease
    • Pharmacogenetics of cholinesterase inhibitors, anti-parkinsonian drugs and antipsychotics
    • Neuroimaging in the dementias

    Research Summary:

    Dr. Masellis has training in four main research areas: cognitive and movement disorders, neurology, pharmacology, and genomics and neuroimaging. His current research focus is on the characterization of the genetics, neuropsychological, neuroimaging and pathological features of atypical neurodegenerative dementias. He is also studying the pharmacogenomics of cholinesterase inhibitors in patients who have dementia associated with Parkinson’s disease and Lewy bodies. He is also looking at the use of anti-parkinsonian medications to treat symptoms of Parkinson’s disease. He has established an “omics” research platform using longitudinal clinical, neuropsychological and neuroimaging data to define biomarkers of drug responses, and of neurodegenerative disease.

    Other research interests include discovery of genomic and epigenomic factors contributing to the complex etiology of neurodegenerative diseases including Alzheimer's disease, Lewy body disease, as well as frontotemporal dementia spectrum disorders. He is also actively involved in clinical trials of novel therapeutic agents in Alzheimer’s disease and Lewy body disease.

    Dr. Masellis is a clinician-scientist and assistant professor within the division of neurology. Clinically, he is a neurologist with expertise in the diagnosis and treatment of early-onset dementias and those dementias associated with movement disorders.

    Selected Publications:

    See current publications list at PubMed.

    1. Misch MR, Mitchell S, Francis PL, Sherborn K, Meradje K, McNeely A, Honjo K, Zhao J, Scott CJM, Caldwell CB, Ehrlich L, Shammi P, MacIntosh BJ, Bilbao JM, Lang AE, Black SE, Masellis M. Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. Alzheimer’s Research & Therapy. Dec 2014;6(9):doi: 10.1186/s13195-014-0071–4.
    2. Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, Morris CM, Theuns J, Crosiers D, Cras P, Engelborghs S, De Deyn PP, Van Broeckhoven C, Mann DMA, Snowden J, Pickering-Brown S, Halliwell N, Davidson Y, Gibbons L, Harris J, Sheerin U, Bras J, Hardy J, Clark L, Marder K, Honig L, Berg D, Maetzler W, Brockmann K, Gasser T, Novellino F, Quattrone A, Annesi G, De Marco EV, Rogaeva E, Masellis M, Black SE, Bilbao JM, Foroud T, Ghetti B, Nichols WC, Pankratz N, Halliday G, Lesage S, Klebe S, Durr A, Duyckaer C, Brice A, Giasson BI, Trojanowski JQ, Hurtig HI, Tayebi N, Landazabal C, Knight MA, Keller M, Singleton AB, Wolfsberg TG, Sidransky E. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurology. Jun 2013;70(6):727–35.
    3. Masellis M, Sherborn K, Rosa-Neto P, Sadovnick DA, Hsiung GYR, Black SE, Prasad S, Williams M, Gauthier S. Early onset dementias: diagnostic and etiological considerations. Alzheimer's Research & Therapy. May 2013. 2013 Jul 31;5(Suppl 1):S7.
    4. Xi Z, Zinman L, Grinberg Y, Moreno D, Sato C, Bilbao JM, Ghani M, Hernández I, Ruiz A, Boada M, Morón FJ, Lang AE, Marras C, Bruni A, Colao R, Maletta RG, Puccio G, Rainero I, Pinessi L, Galimberti D, Morrison KE, Moorby C, Stockton JD, Masellis M, Black SE, Hazrati LN, Liang Y, van Haersma de J With, Fornazzari L, Villagra R, Rojas-Garcia R, Clarimón J, Mayeux R, Robertson J, St George-Hyslop P, and Rogaeva E. Investigation of C9orf72 in four neurodegenerative disorders. JAMA Neurology. Dec 2012;69(12):1583¬–90.
    5. Kalia LV, Mozessohn L, Aviv R, Da Costa L, Lang AE, Shadowitz S, Masellis M. Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly (DVA). Neurology. Mar 2012;78(11): 838–839.

    Related News and Stories:

    Related Links: